Does Bayer's Intervet bid signal hunger for deals?

Bayer may have lost out in the bidding for Schering-Plough's animal health business, but another deal may be in the company's near future. And that willingness to deal is a turnabout from CEO Werner Wenning's (photo) stated priorities back in March.

Wenning offered $8.5 billion for Schering's Intervet unit, sources told Bloomberg, and had gone so far as to put some financing in place. Bayer had commitments from three banks and was considering a securities offering to help finance the deal. But Schering's merger partner Merck elected to keep Intervet and sell its 50 percent share in Merial to partner Sanofi-Aventis.

If the Intervet deal had gone through, it would have been Bayer's second-largest acquisition to its takeover of Schering AG in 2006, Bloomberg reports. And it would have helped Wenning continue to pump up the healthcare side of Bayer's business. Sources told the news service that the CEO may now scout for buyout targets in the U.S. and Asia.

- read the Bloomberg piece

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.